MBO & Co invests in skin care brand Laboratoires Embryolisse to support a new phase of development.

Laboratoires Embryolisse is born in the 1950s, when a Paris hospital dermatologist specializing in skin diseases created the Lait Crème Concentré®.  This unique product gradually became a point of reference thanks to its nourishing, moisturizing, and softening properties. From this expertise was born a full range of skin care products, which are unique in that they are approved by dermatologists, pharmacists and makeup professionals.

Laboratoires Embryolisse has achieved tremendous growth in recent years, led by Nazoura and Alain Cassam-Chenaï, Managing Director and Chairman respectively, who took over the label at the end of the 1990s. They repositioned the brand, developed B2B channels, and expanded into foreign markets. This policy is now bearing fruit, with the company forecasting sales of nearly €30 million this year, half of which expected from exports.

Now Embryolisse’s husband-and-wife team wish to accelerate the company’s growth by partnering with an investor that will acquire a significant stake in the company and that can support them in a transformation project. MBO & Co is acquiring a minority stake in the company, with an investment of €16 million.

Through ambitious structuring and development, Nazoura and Alain Cassam-Chenaï aim to double the size of operations. Their strategic plan consists of: (i) consolidating positions with pharmacy and parapharmacy networks in France; (ii) strengthening sales abroad and expanding into new countries; (iii) digitalising distribution channels through the development of an e-commerce platform, while at the same time (iv) continuing to enrich the product range with innovative formulas, developing the brand’s DNA.